DK1659112T3 - Arylpiperazinderivater som selektiv ligand for dopamin D3 receptor - Google Patents

Arylpiperazinderivater som selektiv ligand for dopamin D3 receptor

Info

Publication number
DK1659112T3
DK1659112T3 DK05292189T DK05292189T DK1659112T3 DK 1659112 T3 DK1659112 T3 DK 1659112T3 DK 05292189 T DK05292189 T DK 05292189T DK 05292189 T DK05292189 T DK 05292189T DK 1659112 T3 DK1659112 T3 DK 1659112T3
Authority
DK
Denmark
Prior art keywords
group
alkyl
fused
optionally
optionally substituted
Prior art date
Application number
DK05292189T
Other languages
Danish (da)
English (en)
Inventor
Marc Capet
Denis Danvy
Nicolas Levoin
Marcel Morvan
Isabelle Berrebi-Bertrand
Thierry Calmels
Philippe Robert
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Application granted granted Critical
Publication of DK1659112T3 publication Critical patent/DK1659112T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
DK05292189T 2004-10-22 2005-10-18 Arylpiperazinderivater som selektiv ligand for dopamin D3 receptor DK1659112T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0411303A FR2877005A1 (fr) 2004-10-22 2004-10-22 Nouveaux derives d'arylpiperazine

Publications (1)

Publication Number Publication Date
DK1659112T3 true DK1659112T3 (da) 2007-10-15

Family

ID=34951190

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05292189T DK1659112T3 (da) 2004-10-22 2005-10-18 Arylpiperazinderivater som selektiv ligand for dopamin D3 receptor

Country Status (14)

Country Link
US (2) US7432269B2 (de)
EP (1) EP1659112B1 (de)
JP (1) JP2006117677A (de)
AT (1) ATE365156T1 (de)
CY (1) CY1107482T1 (de)
DE (1) DE602005001434T2 (de)
DK (1) DK1659112T3 (de)
ES (1) ES2289671T3 (de)
FR (1) FR2877005A1 (de)
HR (1) HRP20070285T3 (de)
PL (1) PL1659112T3 (de)
PT (1) PT1659112E (de)
RS (1) RS50475B (de)
SI (1) SI1659112T1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101861317B (zh) * 2007-03-29 2013-07-31 A.B.英特尔法玛有限公司 抗组胺类抗过敏剂及其制备方法
EP2238125A1 (de) * 2008-02-01 2010-10-13 NeuroSearch A/S Neue aryl-piperazin-derivate als modulatoren von dopamin- und serotonin-rezeptoren
HU1000676D0 (en) * 2010-12-17 2011-02-28 Pharmahungary 2000 Kft Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved
CN112745261A (zh) * 2020-02-27 2021-05-04 广东聚华印刷显示技术有限公司 电子传输材料及其制备方法、电子器件和显示装置

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1450443A (fr) 1965-01-05 1966-06-24 Inst Orch Khim An Ukr Ssr 2-mercapto-5-aryloxazoles et leur procédé de préparation
DE2143730A1 (de) 1971-09-01 1973-03-08 Byk Gulden Lomberg Chem Fab Substituierte pyridine, verfahren zu deren herstellung und sie enthaltende arzneimittel
BE792206A (de) * 1971-12-02 1973-06-01 Byk Gulden Lomberg Chem Fab
EP0036638A3 (de) 1980-03-24 1982-10-20 Diamond Shamrock Corporation Herbizide und das Pflanzenwachstum regulierende 2-Sulfinyl- und 2-Sulfonyl-pyridin-N-Oxide
ZA854887B (en) * 1985-06-27 1986-02-26 Beiersdorf Ag Benzo(c)(1,8)naphthyridines processes for their preparation and their use,and formulations containing these compounds
US4843077A (en) * 1987-06-09 1989-06-27 Ortho Pharmaceutical Corporation Isoquinoline derivatives having renal vasodilating properties and/or cardiotonic properties and/or phosphodiesterase inhibiting properties
FR2672052B1 (fr) * 1991-01-28 1995-05-24 Esteve Labor Dr Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments.
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
TW593290B (en) * 1996-05-10 2004-06-21 Janssen Pharmaceutica Nv Alkylaminobenzothiazole and -benzoxazole derivatives
JP2002504125A (ja) * 1997-06-13 2002-02-05 ニューロゲン コーポレイション ドーパミンｄ▲下４▼リガンドとしての２−アミノアルキルアミノキノリン
US6313141B1 (en) * 1997-06-13 2001-11-06 Neurogen Corporation 2-aminoalkylaminoquinolines as dopamine D4 ligands
AU1122399A (en) * 1997-10-27 1999-05-17 Neurogen Corporation Novel 1-(n'-(arylalkylaminoalkyl))aminoisoindoles; a new class of dopamine receptor subtype specific ligands
US6031097A (en) * 1997-10-27 2000-02-29 Neurogen Corporation 1-(N-(arylalkylaminoalkyl) aminoisoquinolines; a new class of dopamine receptor subtype specific ligands
CN1325397A (zh) * 1998-09-30 2001-12-05 纽罗根公司 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
IL157412A0 (en) * 2001-02-16 2004-03-28 Aventis Pharmaceuticals Inc Av Novel heterocyclic amide derivatives and their use as dopamine d3 receptor ligands
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Also Published As

Publication number Publication date
HRP20070285T3 (en) 2007-08-31
JP2006117677A (ja) 2006-05-11
EP1659112B1 (de) 2007-06-20
DE602005001434T2 (de) 2008-02-07
RS50475B (sr) 2010-03-02
US7432269B2 (en) 2008-10-07
FR2877005A1 (fr) 2006-04-28
US20080167320A1 (en) 2008-07-10
DE602005001434D1 (de) 2007-08-02
EP1659112A1 (de) 2006-05-24
PT1659112E (pt) 2007-09-27
CY1107482T1 (el) 2013-03-13
ES2289671T3 (es) 2008-02-01
US20060089364A1 (en) 2006-04-27
PL1659112T3 (pl) 2007-11-30
ATE365156T1 (de) 2007-07-15
SI1659112T1 (sl) 2007-12-31

Similar Documents

Publication Publication Date Title
NZ601408A (en) Novel 3-hydroxy-5-arylisothiazole derivative
US20120184583A1 (en) Modulators of atp-binding cassette transporters
PH12012500643A1 (en) Novel phenol derivative
RU2011146363A (ru) Производные n-ацил-n-фенилпиперазина, используемые (кроме того) для профилактики или лечения диабета
ES2572148T3 (es) Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
AR065337A1 (es) Proceso para la sintesis de compuestos de 2- aminotiazol como inhibidores de quinasa, forma polimorfica
NO20080728L (no) Nye 1,4-benzotiazepin-1,1-dioksidderivater som har forbedrede egenskaper, fremgangsmate for fremstilling derav, medikamenter inneholdende nevnte forbindelsene og anvendelse derav
PE20081404A1 (es) Derivados de sulfonil-fenil-2h-[1,2,4]oxadiazol-5-ona y procesos para su preparacion
HRP20070285T3 (en) Arylpiperazuine derivatives as selective ligand for the dopamine d3 receptor
WO2007041494A3 (en) Cholesteryl ester transfer protein inhibitors
DE60220694D1 (de) Alkyletherderivate oder deren salze
GEP20135730B (en) Trans-4-{2-[4-(2,3-dichlorophe-nyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treatment of schizophrenia
EP1783116B1 (de) 2-phenylpyridinderivat
Miao et al. Synthesis and potential antibacterial activity of new rhodanine-3-acetic acid derivatives
DE60128239D1 (de) Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten
NO20080816L (no) Anvendelse av delmopinol ved behandling av kviser
AR058698A1 (es) Carbonatos de fenicol con accion antibiotica y composicion farmaceutica
DE602005006018D1 (de) Arylpiperazinderivate und deren verwendung als für den dopamin-d3-rezeptor selektive liganden
ATE518538T1 (de) Verwendung von substituierten piperazin- und morpholinderivaten
NO20052475L (no) Acylderivater av 5-(2-(4-(1,2 benzotiazol-3-yl)-1-piperazinyl)etyl)-6-klor-1,3-dihydro-2H-indol-2-on med neuroleptisk aktivitet.
MY144554A (en) Pharmaceutical composition comprising 2,3-dihydro-6-nitroimidazo[2,1-b]oxazole derivatives
WO2007107663A3 (fr) Utilisation du (3s)-n-hydroxy-4-({4-[(4-hydroxy-2-butynyl)oxy]phényl}sulfonyl)-2,2-diméthyl-3-thiomorpholine carboxamide ou du (s)-n-hydroxy-4-(4-but-2-ynyloxy-benzenesulfonyl) -2,2-dimethyl-thiomorpholine -3-carboxamide dans le traitement de pathologies inflammatoires cutanées
ATE479653T1 (de) Carboxyalkoxy-substituierte acyl-carboxyphenyl- harnstoffderivate, verfahren zu ihre herstellung und ihre verwendung als arzneimittel
HRP20070524T3 (en) CINNAMATES OF BENZO[b]PYRANO[3,2-h]ACRIDIN-7-ONE, PROCESS FOR PREPARATION THEREOF AND THEIR PHARMACEUTICAL COMPOSITION
BRPI0518862A2 (pt) compostos, composiÇço farmacÊutica, mÉtodo para preparar uma composiÇço, e, uso de um composto